Immunoscript Acquires Gennova’s mRNA Division in INR 139 Crore Transaction;Agram Legal Partners Advises

Date:

Share post:

Agram Legal Partners has successfully acted as legal counsel for Immunoscript Life Science Private Limited and its promoter, Dr.Sanjay Singh, in connection with the slump sale acquisition of the mRNA business of Gennova Biopharmaceuticals Limited. Gennova is a subsidiary of Emcure Pharmaceuticals Limited. 

The landmark transaction is valued at approximately INR 139 crore. In addition to the slump sale acquisition of the mRNA business, the comprehensive transaction structure included the sale of Dr. Sanjay Singh’s minority stake in GennovaBiopharmaceuticals Limited to Emcure Pharmaceuticals Limited.

Agram Legal Partners advised on all legal dimensions of the transaction. The firm’s scope of work encompassed strategic negotiation, structuring, drafting, and finalization of all key transaction documents, providing end-to-end legal guidance across every phase of the deal.

The deal team at Agram Legal Partners was led by KhusnumaNagwaswalla, with critical support provided by Suyash Bansal.

This strategic acquisition marks a pivotal moment for Immunoscript Life Science Private Limited as it enhances its market position and expands its footprint in the cutting-edge mRNA technology sector. The successful closing underscores Agram Legal Partners’ core expertise in handling complex healthcare and pharmaceutical M&A transactions on Deal Street.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Apollo Hospitals Launches ‘Always Open, Always Here’, A Global First in Healthcare From India

Avalon Pharma and Bio-Thera Solutions, Ltd. announced an exclusive licensing and commercialization agreement for BAT2406, a proposed biosimilar...

AMTZ LTD Celebrates a Decade of Transforming Healthcare Innovation and Indigenous Manufacturing

AMTZ LTD marks a historic milestone as it completes 10 remarkable years of pioneering innovation, manufacturing excellence, and...

ViiV Healthcare Advances HIV Care with Breakthrough Long-Acting Injectable Data at AIDS 2026

ViiV Healthcare, the global specialist HIV company majority-owned by GSK plc, announced landmark clinical, real-world, and pipeline data...

Wockhardt Launches “Wockhardt Antibiotic Academy” to Tackle Growing Threat of Multidrug Resistance in India

Wockhardt Limited announced the launch of the Wockhardt Antibiotic Academy, a national initiative dedicated to fostering patient-centric scientific dialogue...